NYSE:ABBVBiotechs
Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?
AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates with manageable safety profiles.
See our latest analysis for AbbVie.
The latest lung cancer data arrives during a strong run for AbbVie, with a 24.32% 90 day share price return and a 31.62% 1 year total shareholder return suggesting that momentum has been building.
If this lung cancer update has...